XIA DA¹, HAN GE², JUNFENG SHI³, CHUNHUA ZHU¹, GUOZHU WANG¹, YUAN FANG^4,*, JIN XU^1,*

Oncology Research, Vol.32, No.7, pp. 1209-1219, 2024, DOI:10.32604/or.2024.045433

Abstract Objective: This study aimed to investigate the role of receptor tyrosine kinase-like orphan receptor 2 (ROR2) in triple-negative breast cancer (TNBC). Methods: ROR2 expression in primary TNBC and metastatic TNBC tissues was analyzed by immunohistochemical staining and PCR. ROR2 expression in TNBC cell lines was detected by PCR and Western blot analysis. The migration, invasion and chemosensitivity of TNBC cells with overexpression or knockdown of ROR2 were examined. Results: ROR2 expression was high in metastatic TNBC tissues. ROR2 knockdown suppressed the migration, invasion and chemoresistance of TNBC cells. ROR2 overexpression in MDA-MB-435 cells promoted the migration, More >

Guoqiang Zhang^*1, Zengyan Liu^†1, Yong Han^*, Xiaohong Wang^*, Zhenlin Yang^*

Oncology Research, Vol.24, No.4, pp. 233-238, 2016, DOI:10.3727/096504016X14648701447977

Abstract Triple-negative breast cancer (TNBC) is associated with high recurrence rates of metastasis and death. miR-509 has been reported to be a tumor suppressor in many cancers, but its effect in TNBC has not yet been identified. In this article, we explored the effects of miR-509 on the malignant phenotype of TNBC cells, including proliferation, apoptosis, migration, and invasion. We transiently transfected TNBC cells, Hs578T, with miR-509 mimic. Upon transfection, the expression of miR-509 was upregulated about 50-fold compared with cells transfected with scramble mimic. Overexpression of miR-509 inhibited cell proliferation, induced cell apoptosis, and suppressed More >

KUAILU LIN^1,2, QIANYU GU², XIXI LAI^2,3,*

BIOCELL, Vol.47, No.12, pp. 2681-2696, 2023, DOI:10.32604/biocell.2023.043298

Abstract Objectives: Triple-negative breast cancer (TNBC) poses a significant challenge due to the lack of reliable prognostic gene signatures and an understanding of its immune behavior. Methods: We analyzed clinical information and mRNA expression data from 162 TNBC patients in TCGA-BRCA and 320 patients in METABRIC-BRCA. Utilizing weighted gene coexpression network analysis, we pinpointed 34 TNBC immune genes linked to survival. The least absolute shrinkage and selection operator Cox regression method identified key TNBC immune candidates for prognosis prediction. We calculated chemotherapy sensitivity scores using the “pRRophetic” package in R software and assessed immunotherapy response using the… More >

EUN SOOK KIM¹, SANGHEE KIM², AREE MOON^1,*

Oncology Research, Vol.31, No.6, pp. 867-875, 2023, DOI:10.32604/or.2023.030411

Abstract Invasion and metastasis are important hallmarks of breast cancer and are the leading cause of patient mortality. Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer characterized by a poor prognosis and a lack of effective targeted therapies. The present study investigated the inhibitory effect of a novel FTY720 derivative on the invasive phenotype of TNBC cells. Here, we showed that a novel compound with an isoxazole ring, 4-(3-Decylisoxazol-5-yl)-1-hydroxy-2-(hydroxymethyl)butan-2-aminium chloride (CM2-II-173), significantly inhibited invasiveness of MDA-MB-231 TNBC cells. Expression of matrix metalloproteinase (MMP)-9 and invasiveness of MCF10A normal breast cells induced by sphingosine-1-phosphate… More >

LAZAR S. POPOVIC^1,2,*, GORANA MATOVINA-BRKO¹, MAJA POPOVIC^1,2, KEVIN PUNIE³, ANA CVETANOVIC^4,5, MATTEO LAMBERTINI^6,7

Oncology Research, Vol.31, No.3, pp. 221-238, 2023, DOI:10.32604/or.2023.028525

Abstract Triple-negative breast cancer (TNBC) is a disease with often an aggressive course and a poor prognosis compared to other subtypes of breast cancer. TNBC accounts for approximately 10%–15% of all diagnosed breast cancer cases and represents a high unmet need in the field. Up to just a few years ago, chemotherapy was the only systemic treatment option for this subtype (1). To date, TNBC is considered a heterogeneous disease. One of the existing classifications is based on the analysis of mRNA expression in 587 TNBC cases, in which Lehman et al. proposed six subtypes of… More > Graphic Abstract

SHUIZHONG CEN^1,#, XIAOJIE PENG^2,#, JIANWEN DENG^3,#, HAIYUN JIN⁴, ZHINAN DENG⁵, XIAOHUA LIN³, DI ZHU³, MING JIN⁶, YANWEN ZHU³, PUSHENG ZHANG³, YUNFENG LUO³, HONGYAN HUANG^3,*

Oncology Research, Vol.31, No.3, pp. 375-388, 2023, DOI:10.32604/or.2023.028256

Abstract Triple-negative breast cancer (TNBC) is characterized by fast growth, high metastasis, high invasion, and a lack of therapeutic targets. Mitosis and metastasis of TNBC cells are two important biological behaviors in TNBC malignant progression. It is well known that the long noncoding RNA AFAP1-AS1 plays a crucial role in various tumors, but whether AFAP1-AS1 is involved in the mitosis of TNBC cells remains unknown. In this study, we investigated the functional mechanism of AFAP1-AS1 in targeting Polo-like Kinase 1 (PLK1) activation and participating in mitosis of TNBC cells. We detected the expression of AFAP1-AS1 in the TNBC… More > Graphic Abstract

Dongliang Zhu^1,*, Jun Yang², Jiaxin Xu³

Oncologie, Vol.24, No.3, pp. 471-482, 2022, DOI:10.32604/oncologie.2022.024062

Abstract G-protein coupled estrogen receptor (GPER) is a transmembrane receptor that mediates non-genomic effects of estrogen. This study aimed to investigate the role of GPER in the stemness formation and malignancies in triple negative breast cancer (TNBC) cells. Spheroids of MDA-MB-468 cells were induced by mammosphere culture, and the proportion of the CD44⁺ /CD24^−/low stem cell subpopulation was detected. Malignant characteristics, expression of GPER and stemness-related markers, and tumorigenesis in a xenograft assay were compared between the mammospheres and adherent cultured cells. The impacts of 17β-estradiol (E2) and the GPER-specific antagonist G15 were studied in in vitro assays.… More >

POOJA JAISWAL¹, VERSHA TRIPATHI¹, ANSHUL ASSAIYA², DHARMENDRA KASHYAP³, RAHUL DUBEY⁴, ANAMIKA SINGH⁴, JANESH KUMAR², HEM CHANDRA JHA³, RAJESH SHARMA⁵, AMIT KUMAR DIXIT⁶, HAMENDRA SINGH PARMAR^1,*

BIOCELL, Vol.46, No.12, pp. 2645-2657, 2022, DOI:10.32604/biocell.2022.021754

Abstract Triple-negative breast cancer (TNBC) cell line MDA-MB-231 is known for Warburg metabolism and defects in mitochondria. On the other hand, dipeptidyl peptidase-IV (DPP-IV) inhibitors such as sitagliptin and vildagliptin and GLP-1 agonist exendin-4 are known to improve mitochondrial functions as well as biogenesis, but no study has evaluated the influence of these drugs on mitochondrial biogenesis on metastatic breast cancer cell line. We have recently reported anticancer effects of 5-aminoimidazole-4-carboxamide riboside on MDA-MB-231 cells via activation of AMP-dependent kinase (AMPK), which activates the downstream transcription factors PGC-1α, PGC-1β, or FOXO1 for mitochondrial biogenesis; above-mentioned incretin-based… More >

Leonard Lothstein^*, Judith Soberman^†, Deanna Parke^*, Jatin Gandhi^*, Trevor Sweatman^‡, Tiffany Seagroves^*

Oncology Research, Vol.28, No.5, pp. 451-465, 2020, DOI:10.3727/096504020X15898794315356

Abstract Triple-negative breast cancer (TNBC) is unresponsive to antiestrogen and anti-HER2 therapies, requiring the use of cytotoxic drug combinations of anthracyclines, taxanes, cyclophosphamide, and platinum compounds. Multidrug therapies achieve pathological cure rates of only 20–40%, a consequence of drug resistance and cumulative dose limitations necessitated by the reversible cardiotoxic effects of drug therapy. Safer and more effective treatments for TNBC are required to achieve durable therapeutic responses. This study describes the mechanistic analyses of the novel anthracycline, pivarubicin, and its in vivo efficacy against human primary TNBC. Pivarubicin directly activates PKCd, triggers rapid mitochondrial-dependent apoptosis, and… More >

LIPING WANG^1,2, ZHOU LUO¹, MINMIN SUN³, QIUYUE YUAN⁴, YINGGANG ZOU⁵, DEYUAN FU^1,*

BIOCELL, Vol.46, No.3, pp. 595-606, 2022, DOI:10.32604/biocell.2022.017337

Abstract This work aimed to improve current prognostic signatures based on clinical stages in identifying high-risk patients of triple-negative breast cancer (TNBC), to allow patients with a high-risk score for specific treatment decisions. In this study, 396 TNBC samples from TCGA and GEO databases were included in genome-wide transcriptome analysis. The relationship between normalized gene expression values and survival data of patients was determined by Cox proportional hazards models in each dataset. The overlapped genes among all datasets were considered as a potential prognostic signature. The risk score was constructed based on individual genes and validated… More >